GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
基本信息
- 批准号:6518620
- 负责人:
- 金额:$ 28.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-08-04 至 2004-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Applicant's Abstract)
Retinal ganglion cell (RGC) death is the final common pathway for glaucoma and
virtually all other optic neuropathies. The initial insult in most optic nerve
diseases is injury to the RGC axon, from either compression, ischemia,
inflammation, or transection. Optic nerve injury results in RGC apoptosis, and
this has been theorized to occur by interference with retrograde transport of
target-derived neurotrophic factors or other mechanisms.
Given that (1) axotomy induces RGC apoptosis and (2) most optic neuropathies
are associated with initial axonal damage and subsequent RGC loss, RGC axotomy
is an experimental model for understanding the pathophysiology of glaucomatous
and other optic neuropathies. Our overall goal is to ascertain the molecular
changes that occur within the RGC after axotomy, particularly those leading to
induction of the apoptosis cascade, as well as hypothetical protective
mechanisms. Our working hypothesis is that one of the critical molecular events
underlying RGC death after axonal injury is generation of an intracellular
reactive oxygen species (ROS) signal. Our long-term goal is to find ways of
preventing RGC death from axonal injury by modulating these mechanisms.
To test this hypothesis, we propose the following: (1) Determine whether
generation of ROS is a necessary and sufficient step for initiation of a series
of events leading to RGC apoptosis after axotomy; (2) Test whether endogenous
regulation of ROS can act as a defense mechanism governing the RGC response to
axotomy; (3) Test whether the mechanism by which ROS signal RGC death after
axotomy involves opening of the mitochondrial permeability transition pore.
Almost all optic neuropathies involve RGC axonal injury, except for a few
disorders where the locus of injury is unknown. If ROS generation is essential
for RGC death after axotomy, then this could serve as a critical point for
therapeutic intervention. The health-relatedness of this proposal is that an
understanding of the molecular response of the RGC to axonal injury would be
applicable to a wide variety of diseases of the optic nerve, independent of the
mechanism by which the nerve is injured. As many of these diseases (e.g.,
normal-tension glaucoma and ischemic optic neuropathy) are not easily
treatable, determination of the regulation of cell destructive and protective
mechanisms could lead to innovative new therapies.
描述:(申请人摘要)
视网膜神经节细胞(RGC)死亡是青光眼和青光眼的最终共同途径
几乎所有其他视神经疾病。最初对大多数视神经的侮辱
疾病是RGC轴突的损伤,要么是受压,要么是缺血,
炎症,或横切。视神经损伤导致RGC细胞凋亡,
这已经被理论上认为是由于干扰了逆行运输
靶向衍生神经营养因子或其他机制。
考虑到(1)轴突切断诱导RGC细胞凋亡和(2)大多数视神经病变
与最初的轴突损伤和随后的RGC丢失、RGC轴突切断有关
是了解青光眼病理生理学的实验模型。
以及其他视神经疾病。我们的总体目标是确定分子
轴突切断后在研资局内发生的变化,特别是导致
诱导细胞凋亡级联反应以及假说的保护作用
机制。我们的工作假设是,关键的分子事件之一
轴突损伤后RGC死亡的潜在原因是细胞内产生
活性氧(ROS)信号。我们的长期目标是找到
通过调节这些机制来预防RGC因轴突损伤而死亡。
为了验证这一假设,我们提出了以下建议:(1)确定是否
ROS的产生是启动一系列活动的必要且充分的步骤
轴突切断后导致RGC细胞凋亡的事件;(2)检测内源性
ROS的调节可以作为一种防御机制,管理RGC对
(3)检测ROS信号转导RGC死亡的机制
轴突切开术涉及打开线粒体通透性转换孔。
几乎所有的视神经病变都与RGC轴突损伤有关,除了少数
损伤部位不明的疾病。如果ROS生成是必不可少的
对于RGC在轴突切断后的死亡,这可能是一个临界点
治疗性干预。这项建议与健康有关的地方是
对RGC对轴突损伤的分子反应的理解将是
适用于多种视神经疾病,不依赖于
神经受损的机制。这些疾病中的许多(例如,
正常眼压性青光眼和缺血性视神经病变)不容易
可治疗,细胞破坏性和保护性调节的测定
这种机制可能会带来创新的新疗法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Leonard A Levin其他文献
Leonard A Levin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Leonard A Levin', 18)}}的其他基金
Development of redox-active therapies for ischemic optic neuropathy
缺血性视神经病氧化还原活性疗法的开发
- 批准号:
8975773 - 财政年份:2014
- 资助金额:
$ 28.8万 - 项目类别:
Development of redox-active therapies for ischemic optic neuropathy
缺血性视神经病氧化还原活性疗法的开发
- 批准号:
8809877 - 财政年份:2014
- 资助金额:
$ 28.8万 - 项目类别:
Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
新型线粒体靶向青光眼神经保护剂
- 批准号:
7917762 - 财政年份:2009
- 资助金额:
$ 28.8万 - 项目类别:
Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
新型线粒体靶向青光眼神经保护剂
- 批准号:
7351810 - 财政年份:2007
- 资助金额:
$ 28.8万 - 项目类别:
Novel Mitochondrial Targeted Neuroprotectants for Glaucoma
新型线粒体靶向神经保护剂治疗青光眼
- 批准号:
7189148 - 财政年份:2007
- 资助金额:
$ 28.8万 - 项目类别:
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
- 批准号:
6195717 - 财政年份:2000
- 资助金额:
$ 28.8万 - 项目类别:
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
- 批准号:
6635669 - 财政年份:2000
- 资助金额:
$ 28.8万 - 项目类别:
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
- 批准号:
6950900 - 财政年份:2000
- 资助金额:
$ 28.8万 - 项目类别:
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
- 批准号:
6384792 - 财政年份:2000
- 资助金额:
$ 28.8万 - 项目类别:
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLS
轴切视网膜神经节细胞中的基因表达
- 批准号:
2710767 - 财政年份:1994
- 资助金额:
$ 28.8万 - 项目类别: